> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Hematologic Disorders Drug Development
- URL: https://www.fdaweb.com/guide-on-hematologic-disorders-drug-development/
- Published: 2019-03-15T12:00:00.000Z
- Updated: 2026-09-15T01:13:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143619

Federal Register notice: FDA made available a final guidance entitled “Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals.” The document outlines nonclinical studies recommended for developing pharmaceuticals used to treat patients with such disorders and addresses comments received to the docket. It is intended to streamline product development, while protecting patients’ safety and avoiding unnecessary use of animals. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-03-15/pdf/2019-04816.pdf?ref=fdaweb.com).